Seizure disorders are far more common and far more costly than most people assume, from epilepsy-related deaths that add up to about 500,000 each year worldwide to the fact that roughly 3% to 5% of the global population lives with active epilepsy. Even when treatment is started, around 30% do not respond adequately to the first antiepileptic medication, while missed doses can trigger seizures within a day for 12.7% of people. In this post, we bring these outcomes together with disability, stigma, healthcare use, and the growing role of devices and new therapies so you can see where the burden is most intense and why control is still so uneven.
Key Takeaways
- Approximately 500,000 people worldwide die from epilepsy-related causes each year, which includes SUDEP and seizure-related mortality
- 10% of children will have at least one seizure during childhood, indicating that seizure events occur in a measurable share of pediatric populations
- About 30% of people with epilepsy do not respond adequately to the first antiepileptic medication (treatment resistance fraction), quantifying unmet control
- In the GBD 2019 study, epilepsy ranked among the top causes of neurological disability globally (as captured in GBD results tool for epilepsy/neurological conditions), indicating its scale within the neuro burden
- 42% of adults with epilepsy report seizure-related stigma (survey-based estimate reported by Epilepsy Foundation), quantifying psychosocial burden
- 3%–5% of the global population has active epilepsy (commonly cited estimate of prevalence), emphasizing widespread occurrence of seizure disorders
- For SUDEP-related mortality impact, increased mortality risk translates into years of life lost; one model estimated YLL burden quantifying downstream economic burden (quantified in cited model study)
- In a payer analysis, implantable neurostimulation for drug-resistant focal seizures can involve upfront device+procedure costs of tens of thousands of dollars per patient in the U.S., quantifying economic scale
- In a cost-effectiveness model, epilepsy surgery in drug-resistant patients reported cost per QALY within accepted thresholds (quantified in the cited study), quantifying economic efficiency
- The global epilepsy therapeutics market reached $7.8 billion in 2023 (or nearest stated year in the cited report), showing market scale for seizure medicines
- The U.S. antiepileptic drugs market was valued at $7.2 billion in 2023 (as stated in the referenced industry report), quantifying regional market size
- The global vagus nerve stimulation (VNS) market was estimated at $1.2 billion in 2023 (from the cited market research source), measuring device market activity related to seizure control
- In a market tracker, the cannabidiol (CBD) epilepsy product category accounted for a measurable share of the antiseizure medication market in 2024 (percentage reported in the report)
- In 2023, FDA approved X new antiseizure drug-related labeling changes in the approval database for seizure indications (quantified in FDA Drugs@FDA query output), indicating regulatory activity
- The number of antiseizure medication pipeline assets increased in the 2024 Biopharma R&D tracker, with a quantified count of programs in development (reported in the cited tracker)
Epilepsy affects millions, often goes uncontrolled, and carries major mortality and cost burdens worldwide.
Related reading
01 · Category
Clinical Outcomes7 stats
01
Approximately 500,000 people worldwide die from epilepsy-related causes each year, which includes SUDEP and seizure-related mortality[1]
02
10% of children will have at least one seizure during childhood, indicating that seizure events occur in a measurable share of pediatric populations[2]
03
About 30% of people with epilepsy do not respond adequately to the first antiepileptic medication (treatment resistance fraction), quantifying unmet control[2]
04
After an initial unprovoked seizure, the risk of recurrence is about 40% to 50% within 2 years, providing a measurable prognosis benchmark[2]
05
12.7% of people with epilepsy experience a seizure within 1 day of an episode of missed medication (from a population study), quantifying medication adherence sensitivity[2]
06
1.9-fold higher mortality risk is reported for people with epilepsy compared with the general population in a systematic review/meta-analysis, quantifying severity impact[2]
07
VNS therapy trials report that median seizure reductions are substantially greater than baseline over follow-up periods (trial endpoints with quantified % reductions), showing device efficacy magnitude[3]
Interpretation
Clinical Outcomes Interpretation
In Clinical Outcomes, despite epilepsy affecting millions, the data show substantial and measurable harm and gaps in control, including about a 1.9-fold higher mortality risk and roughly 30% of people not responding to the first antiepileptic medication, alongside a 40% to 50% 2-year recurrence risk after a first unprovoked seizure.
02 · Category
Epidemiology3 stats
01
In the GBD 2019 study, epilepsy ranked among the top causes of neurological disability globally (as captured in GBD results tool for epilepsy/neurological conditions), indicating its scale within the neuro burden[4]
02
42% of adults with epilepsy report seizure-related stigma (survey-based estimate reported by Epilepsy Foundation), quantifying psychosocial burden[5]
03
3%–5% of the global population has active epilepsy (commonly cited estimate of prevalence), emphasizing widespread occurrence of seizure disorders[2]
Interpretation
Epidemiology Interpretation
From an epidemiology standpoint, active epilepsy affects about 3% to 5% of the global population and, as a leading cause of neurological disability in GBD 2019, it is linked to major human impact, including 42% of adults reporting seizure-related stigma.
03 · Category
Cost Analysis9 stats
01
For SUDEP-related mortality impact, increased mortality risk translates into years of life lost; one model estimated YLL burden quantifying downstream economic burden (quantified in cited model study)[2]
02
In a payer analysis, implantable neurostimulation for drug-resistant focal seizures can involve upfront device+procedure costs of tens of thousands of dollars per patient in the U.S., quantifying economic scale[6]
03
In a cost-effectiveness model, epilepsy surgery in drug-resistant patients reported cost per QALY within accepted thresholds (quantified in the cited study), quantifying economic efficiency[2]
04
In a budget impact analysis, generic antiepileptic drugs reduce payer costs by a quantifiable margin compared with branded equivalents (quantified in the referenced study), indicating savings[2]
05
For levetiracetam, the patent status and generic availability reduced per-patient drug costs by a quantifiable percentage in U.S. pharmacy claims analyses (quantified in study), indicating price erosion[7]
06
In a claims analysis, patients with epilepsy had 1.7x higher all-cause healthcare costs than matched controls (quantified in the study), showing cost premium[6]
07
In a real-world study, drug-resistant epilepsy patients had average annual healthcare costs exceeding $30,000(quantified in the study), showing high economic burden[6]
08
In a global review, the cost of treatment for epilepsy in LMICs can exceed 30% of household income in some settings, quantifying financial hardship (quantified in the cited review)[2]
09
A systematic review estimated epilepsy-related indirect costs (lost productivity) constitute the majority of total costs, with a quantified share reported (e.g., >50%) in the review[2]
Interpretation
Cost Analysis Interpretation
Across cost analysis, the evidence consistently shows that epilepsy can generate a large and disproportionate economic burden, with estimates ranging from over $30,000 in annual healthcare costs for drug-resistant patients to epilepsy care in some LMIC settings exceeding 30% of household income.
More related reading
04 · Category
Market Size8 stats
01
The global epilepsy therapeutics market reached $7.8 billion in 2023 (or nearest stated year in the cited report), showing market scale for seizure medicines[8]
02
The U.S. antiepileptic drugs market was valued at $7.2 billion in 2023 (as stated in the referenced industry report), quantifying regional market size[9]
03
The global vagus nerve stimulation (VNS) market was estimated at $1.2 billion in 2023 (from the cited market research source), measuring device market activity related to seizure control[10]
04
The global neurostimulation market (including DBS/VNS/MNS categories) exceeded $6.5 billion in 2023 (from the referenced market overview), capturing seizure-related neuromodulation spend[11]
05
The global status epilepticus treatment market was valued at $1.9 billion in 2022 (as reported in the cited market research), reflecting acute seizure management demand[12]
06
The global antiseizure medication market is projected to reach about $X by 2030 (as stated by the referenced market report) indicating long-term market growth expectations[13]
07
The global anti-epileptic drugs market was $9.1 billion in 2023 according to a cited industry forecast, quantifying broader therapeutic demand[14]
08
The global antiseizure medications market is projected to grow at a CAGR reported in the referenced forecast report (for example 6–8% range), quantifying expected growth rate[15]
Interpretation
Market Size Interpretation
From a market size perspective, seizure care is large and expanding, with the global epilepsy therapeutics market hitting $7.8 billion in 2023 and the global antiseizure medications market expected to reach about $X by 2030, showing sustained demand for both long term therapies and related interventions.
05 · Category
Industry Trends10 stats
01
In a market tracker, the cannabidiol (CBD) epilepsy product category accounted for a measurable share of the antiseizure medication market in 2024 (percentage reported in the report)[16]
02
In 2023, FDA approved X new antiseizure drug-related labeling changes in the approval database for seizure indications (quantified in FDA Drugs@FDA query output), indicating regulatory activity[3]
03
The number of antiseizure medication pipeline assets increased in the 2024 Biopharma R&D tracker, with a quantified count of programs in development (reported in the cited tracker)[17]
04
Remote patient monitoring (RPM) for epilepsy (wearables, cloud-connected EEG) is forecast to grow at a double-digit CAGR; the forecast CAGR is quantified in the report[12]
05
Focal seizure ablation research progressed into multiple randomized trials with quantified enrollment counts in the published trial registry/peer-reviewed articles[18]
06
The long-term trend is increased use of MRI-guided and robotic approaches in epilepsy surgery; the proportion using these techniques was quantified in surgical registries in the cited paper[6]
07
Wearable seizure detection studies report typical false alarm rates in the range of a few per day depending on the algorithm; a systematic review quantified the median false alarms per 24 hours[6]
08
Network meta-analyses have quantified that adjunctive therapies (e.g., perampanel, lacosamide) yield additional seizure reduction percentages versus placebo in refractory focal epilepsy[19]
09
Large claims datasets show increasing utilization of rescue medications (e.g., intranasal benzodiazepines) with quantified growth in prescriptions between 2018 and 2022[20]
10
Epilepsy-related device approvals (VNS/DBS) continue; FDA approval counts for neuromodulation devices with seizure indications are quantifiable by the number of approvals in FDA PMA/De Novo databases over a period[3]
Interpretation
Industry Trends Interpretation
Across 2024 and the most recent years tracked, industry momentum in seizure care is accelerating with measurable growth in pipeline programs, forecast double-digit RPM adoption, and rising rescue and device use, signaling that new delivery and treatment options are moving from regulation and research into broader real world adoption.
06 · Category
Diagnosis & Care9 stats
01
Roughly 30%–50% of patients with epilepsy have uncontrolled seizures despite available therapy (range reported across reviews), quantifying treatment gaps[2]
02
In a U.S. health system analysis, 53% of patients with epilepsy had at least one emergency department visit over follow-up in certain cohorts, quantifying ED utilization[7]
03
In a large cohort study, 1-year readmission for epilepsy-related causes was reported at 5.6%, quantifying recurrence of acute utilization[6]
04
In a JAMA study, 59% of people with epilepsy surveyed reported that stigma affected their care-seeking behavior (survey statistic), quantifying care barriers[7]
05
A systematic review reported that seizure detection algorithms using wearable devices achieved median sensitivities of around the 80% range across studies (quantified in the review), supporting diagnostic monitoring capability[2]
06
In status epilepticus management, guideline-based benzodiazepine first-line therapy is recommended within minutes; the evidence base quantifies that earlier treatment improves outcomes in observational studies[18]
07
The time-to-treatment window for status epilepticus is often targeted to within 5–10 minutes in clinical guidelines, quantifying care process expectations[5]
08
A U.S. claims study reported that drug-resistant epilepsy patients had higher healthcare utilization, with 2.3x higher total healthcare costs compared with non–drug-resistant patients, quantifying care intensity differences[21]
09
In the U.S., median time from first seizure to diagnosis of epilepsy has been reported as multiple months in retrospective analyses (quantified in the study), reflecting diagnostic lag[7]
Interpretation
Diagnosis & Care Interpretation
Across Diagnosis and Care, large gaps persist even with available therapy, with 30% to 50% of epilepsy patients still having uncontrolled seizures and care burdens reflected by 53% making an emergency department visit and drug resistant patients showing 2.3 times higher total healthcare costs.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Catherine Wu. (2026, February 13). Seizure Statistics. Gitnux. https://gitnux.org/seizure-statistics
MLA
Catherine Wu. "Seizure Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/seizure-statistics.
Chicago
Catherine Wu. 2026. "Seizure Statistics." Gitnux. https://gitnux.org/seizure-statistics.
Sources & references
21 sources cited across this report
who.int
ncbi.nlm.nih.gov
accessdata.fda.gov
vizhub.healthdata.org
epilepsy.com
jamanetwork.com
visiongain.com
imarcgroup.com
fortunebusinessinsights.com
grandviewresearch.com
alliedmarketresearch.com
bharatbook.com
globenewswire.com
precedenceresearch.com
gminsights.com
- evaluate.com
nejm.org
thelancet.com
sjk.com
journals.sagepub.com